Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJV6 | ISIN: NL00150002Q7 | Ticker-Symbol: 05Y
Tradegate
27.06.25 | 16:21
1,460 Euro
-0,41 % -0,006
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VIVORYON THERAPEUTICS NV Chart 1 Jahr
5-Tage-Chart
VIVORYON THERAPEUTICS NV 5-Tage-Chart
RealtimeGeldBriefZeit
1,4601,46616:27
1,4621,47016:22

Aktuelle News zur VIVORYON THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
VIVORYON THERAPEUTICS Aktie jetzt für 0€ handeln
07:10Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences200Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences Halle (Saale) / Munich, Germany, June 27, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon)...
► Artikel lesen
DiVivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting269Vivoryon Therapeutics N.V. Reports Outcomeof 2025 Annual General Meeting Halle (Saale) / Munich, Germany, June 24, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon)...
► Artikel lesen
18.06.Vivoryon Therapeutics N.V.: Online-Präsentation für Investoren am 01.07.2025421Vivoryon ist ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung innovativer, kleinmolekularer Arzneimittel zur Behandlung entzündlicher und fibrotischer...
► Artikel lesen
17.06.Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress374Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Continued progress in advancing varoglutamstat in kidney disease based on encouraging data and expansion of IP portfolioVaroglutamstat's...
► Artikel lesen
11.06.Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025386Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025 Halle To join the conference call via phone, participants may pre-register and will receive...
► Artikel lesen
06.06.Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025356Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam:...
► Artikel lesen
27.05.Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat402Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat Newly granted U.S. patent expected to provide exclusivity...
► Artikel lesen
13.05.Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025429Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meetingon June 24, 2025 Halle. ### About Vivoryon Therapeutics N.V.Vivoryon is a clinical stage biotechnology company focused on...
► Artikel lesen
29.04.Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update591Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update Successful strategic shift towards a focus on inflammatory and fibrotic diseases, in particular on...
► Artikel lesen
24.04.Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million436Vivoryon Therapeutics N.V. Signs Financing Agreementfor up to EUR 15 Million Halle (Saale) / Munich, Germany, April 24, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...
► Artikel lesen
17.04.Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025365Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025 Halle).Conference call detailsDate: April 29, 2025Time: 3:00 pm CEST / 9:00 am EDTThe...
► Artikel lesen
19.02.Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers601Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers Halle (Saale) / Munich, Germany, February 19, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...
► Artikel lesen
11.02.Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025539Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025 Halle (Saale) / Munich, Germany, February 11, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam:...
► Artikel lesen
14.01.Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease848Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease A meta-analysis of VIVIAD and VIVA-MIND1 data confirmed that treatment with varoglutamstat...
► Artikel lesen
10.12.24Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease964Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease Varoglutamstat Phase 2 program shows highly consistent, statistically significant and...
► Artikel lesen
09.12.24Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat's Potential to Improve Kidney Function924Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data fromVIVA-MIND Strongly Supporting Varoglutamstat's Potential toImprove Kidney Function VIVA-MIND Phase 2 data confirm results of varoglutamstat's...
► Artikel lesen
04.12.24Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024774Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Halle (Saale) / Munich, Germany, December 04, 2024 - Vivoryon Therapeutics N.V....
► Artikel lesen
26.10.24Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 20241.328Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Selected for late-breaking oral presentation at ASN kidney week, the...
► Artikel lesen
11.10.24Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 20241.051Halle (Saale) / Munich, Germany, October 11, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of...
► Artikel lesen
01.10.24Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event968Halle (Saale) / Munich, Germany, October 1, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of...
► Artikel lesen
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,7